Details of the Drug
General Information of Drug (ID: DMAFS7J)
Drug Name |
1-(2-hydroxyphenyl)-3-p-tolylprop-2-en-1-one
|
||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
2'-Hydroxy-4-methylchalcone; 1-(2-hydroxyphenyl)-3-(4-methylphenyl)prop-2-en-1-one; (2E)-1-(2-hydroxyphenyl)-3-(4-methylphenyl)prop-2-en-1-one; AC1NTAGW; 2-Propen-1-one, 1-(2-hydroxyphenyl)-3-(4-methylphenyl)-; 4-Methyl-2'-hydroxychalcone; MLS000777737; CHEMBL476598; SCHEMBL2807968; MolPort-000-648-204; OOEWKJHFFYCQBM-ZHACJKMWSA-N; Chalcone, 2'-hydroxy-4-methyl-; HMS2760H03; ZX-AT026696; ZINC4252606; 2'-Hydroxy-4-methyl-trans-chalcone; STK530118; AKOS005463239; SMR000414122; ST098968; 2'-Hydroxy-4-methylchalcone, AldrichCPR
|
||||||||||||||||||||||
Indication |
|
||||||||||||||||||||||
Drug Type |
Small molecular drug
|
||||||||||||||||||||||
Structure | |||||||||||||||||||||||
3D MOL | 2D MOL | ||||||||||||||||||||||
#Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 238.28 | |||||||||||||||||||||
Logarithm of the Partition Coefficient (xlogp) | 4.3 | ||||||||||||||||||||||
Rotatable Bond Count (rotbonds) | 3 | ||||||||||||||||||||||
Hydrogen Bond Donor Count (hbonddonor) | 1 | ||||||||||||||||||||||
Hydrogen Bond Acceptor Count (hbondacc) | 2 | ||||||||||||||||||||||
Chemical Identifiers |
|
||||||||||||||||||||||
Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
The Studied Disease | Discovery agent | |||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ICD Disease Classification | N.A. | |||||||||||||||||||||||
|
||||||||||||||||||||||||
Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||